Positive feedback loops drive immune cell polarization toward a pro-tumor phenotype that accentuates immunosuppression and tumor angiogenesis. This phenotypic switch leads to the escape of cancer cells from immune destruction. These positive feedback loops are generated by cytokines such as TGF- β , Interleukin-10 and Interleukin-4, which are responsible for the polarization of monocytes and M1 macrophages into pro-tumor M2 macrophages, and the polarization of naive helper T cells intopro-tumor Th2 cells. In this article, we present a deterministic ordinary differential equation (ODE) model that includes key cellular interactions and cytokine signaling pathways that lead to immune cell polarization in the tumor microenvironment. The model was used to simulate various cancer treatments in silico. We identified combination therapies that consist of M1 macrophages or Th1 helper cells, coupled with an anti-angiogenic treatment, that are robust with respect to immune response strength, initial tumor size and treatment resistance. We also identified IL-4 and IL-10 as the targets that should be neutralized in order to make these combination treatments robust with respect to immune cell polarization. The model simulations confirmed a hypothesis based on published experimental evidence that a polarization into the M1 and Th1 phenotypes to increase the M1-to-M2 and Th1-to-Th2 ratios plays a significant role in treatment success. Our results highlight the importance of immune cell reprogramming as a viable strategy to eradicate a highly vascularized tumor when the strength of the immune response is characteristically weak and cell polarization to the pro-tumor phenotype has occurred.
Andersen, M.H. (2015) Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. Journal of the National Cancer Institute, 107, djv154-djv154. https://doi.org/10.1093/jnci/djv154
Nouroz, F., Bibi, F., Noreen, S. and Masood, N. (2016) Natural Killer Cells Enhance the Immune Surveillance of Cancer. The Egyptian Journal of Medical Human Genetics, 17, 149-154. https://doi.org/10.1016/j.ejmhg.2015.08.006
Zhang, M.m et al. (2014) A high M1/M2 Ratio of Tumor-Associated Macrophages Is Associated with Extended Survival in Ovarian Cancer Patients. Journal of Ovarian Research, 7, 19. https://doi.org/10.1186/1757-2215-7-19
Den Breems, N.Y. and Eftimie, R. (2016) The Re-Polarisation of M2 and M1 Macrophages And Its Role on Cancer Outcomes. Journal of Theoretical Biology, 390, 23-39. https://doi.org/10.1016/j.jtbi.2015.10.034
Bergmann, C., Van Hemmen, J.L. and Segel, L.A. (2001) Th1 or Th2: How an Appropriate T Helper Response Can Be Made. Bulletin of Mathematical Biology, 63, 405-431. https://doi.org/10.1006/bulm.2000.0215
Kogan, Y., Agur, Z. and Elishmereni, M. (2013) A Mathematical Model for the Immunotherapeutic Control of the Th1/Th2 Imbalance in Melanoma. Discret. Contin. Dyn. Syst. - Ser. B, 18, 1017-1030.
Shurin, M.R., Lu, L., Kalinski, P., Stewart-Akers, A.M. and Lotze, M.T. (1999) Th1/Th2 Balance in Cancer, Transplantation and Pregnancy. Springer Seminars In immunopathology, 21, 339-359. https://doi.org/10.1007/BF00812261
Wang, X.L., et al. (2017) High Infiltration of CD68-Tumor Associated Macrophages, Predict Poor Prognosis in Kazakh Esophageal Cancer Patients. International Journal of Experimental Pathology, 10, 10282-10292.
Yafei, Z., Jun, G. and Guolan, G. (2016) Correlation between Macrophage Infiltration and Prognosis of Ovarian Cancer—A Preliminary Study. Biomedical Research, 27, No. 2.
Tanaka, A. and Sakaguchi, S. (2017) Regulatory T Cells in Cancer Immunotherapy. Cell Research, 27, 109-118. https://doi.org/10.1038/cr.2016.151
Tosolini, M., et al. (2011) Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, th2, treg, th17) in Patients with Colorectal Cancer. Cancer Research, 71, 1263-1271. https://doi.org/10.1158/0008-5472.CAN-10-2907
Zheng, X., et al. (2017) Redirecting Tumor-Associated Macrophages to Become Tumoricidal Effectors as a Novel Strategy for Cancer Therapy. Oncotarget, 8, 48436-48452. https://doi.org/10.18632/oncotarget.17061
Modeling Macrophage Polarization and Its Effect on Cancer Treatment Success — Oak Academic Publishing
Genard, G., Lucas, S. and Michiels, C. (2017) Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Frontiers in Immunology, 8, 828. https://doi.org/10.3389/fimmu.2017.00828
Fridlender, Z.G., et al. (2013) Using Macrophage Activation to Augment Immunotherapy of Established Tumours. British Journal of Cancer, 108, 1288-1297. https://doi.org/10.1038/bjc.2013.93
Brown, J.M., Recht, L. and Strober, S. (2017) The Promise of Targeting Macrophages in Cancer Therapy. Clinical Cancer Research, 23, 3241-3250. https://doi.org/10.1158/1078-0432.CCR-16-3122
Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity, 41, 49-61. https://doi.org/10.1016/j.immuni.2014.06.010
La Flamme, A.C., Kharkrang, M., Stone, S., Mirmoeini, S., Chuluundorj, D. and Kyle, R. (2012) Type II-Activated Murine Macrophages Produce IL-4. PLoS One, 7, e46989. https://doi.org/10.1371/journal.pone.0046989
Neurath, M.F., Fichtner-Feigl, S. and Kesselring, R. (2015) Intestinal Inflammation and Cancer of the Gastrointestinal Tract. In: Mucosal Immunology, Elsevier, Amsterdam, 1761-1775. https://doi.org/10.1016/B978-0-12-415847-4.00091-4
Romagnani, S. (1992) Type 1 T Helper and Type 2 T Helper Cells: Functions, Regulation and Role in Protection and Disease. International Journal of Clinical and Laboratory Research, 21, 152-158. https://doi.org/10.1007/BF02591635
Chen, W., et al. (2003) Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-Beta Induction of Transcription Factor Foxp3. Journal of Experimental Medicine, 198, 1875-1886. https://doi.org/10.1084/jem.20030152
Mitrophanov, A.Y. and Groisman, E.A. (2008) Positive Feedback in Cellular Control Systems. Bioessays, 30, 542-555. https://doi.org/10.1002/bies.20769
Ingolia, N.T. and Murray, A.W. (2007) Positive-Feedback Loops as a Flexible Biological Module. Current Biology, 17, 668-677. https://doi.org/10.1016/j.cub.2007.03.016
Burkholder, B., et al. (2014) Tumor-Induced Perturbations of Cytokines and Immune Cell Networks. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1845, 182-201. https://doi.org/10.1016/j.bbcan.2014.01.004
Fernandez, M., Zhou, M. and Soto-Ortiz, L. (2018) A Computational Assessment of the Robustness of Cancer Treatments with Respect to Immune Response Strength, Tumor Size and Resistance. International Journal of Tumor Therapy, 7, 1-19.
Sameen, S., Barbuti, R., Milazzo, P., Cerone, A., Del Re, M. and Danesi, R. (2016) Mathematical Modeling of Drug Resistance Due to KRAS Mutation in Colorectal Cancer. Journal of Theoretical Biology, 389, 263-273. https://doi.org/10.1016/j.jtbi.2015.10.019
Jounaidi, Y., Cotten, J.F., Miller, K.W. and Forman, S.A. (2017) Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells. Cancer Research, 77, 5938-5951. https://doi.org/10.1158/0008-5472.CAN-17-1007
Kim, H., Kwon, B. and Sin, J.-I. (2013) Combined Stimulation of IL-2 and 4-1BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-Specific CTL Responses. PLoS One, 8, e83765. https://doi.org/10.1371/journal.pone.0083765
Liu, C., Workman, C.J. and Vignali, D.A.A. (2016) Targeting Regulatory T Cells in Tumors. The FEBS Journal, 283, 2731-2748. https://doi.org/10.1111/febs.13656
Martinez, F.O. and Gordon, S. (2014) The M1 and M2 Paradigm of Macrophage Activation: Time for Reassessment. F1000 Prime Reports, 6, 13. https://doi.org/10.12703/P6-13
Magombedze, G., Reddy, P.B.J., Eda, S. and Ganusov, V.V. (2013) Cellular and Population Plasticity of Helper CD4+ T Cell Responses. Frontiers in Physiology, 4, 206. https://doi.org/10.3389/fphys.2013.00206
Hao, W., Schlesinger, L.S. and Friedman, A. (2016) Modeling Granulomas in Response to Infection in the Lung. PLoS One, 11, e0148738. https://doi.org/10.1371/journal.pone.0148738
de Pillis, L.G., Savage, H. and Radunskaya, A.E. (2014) Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments. British Journal of Medicine and Medical Research, 4, No. 16.
Kim, K.S., Cho, G. and Jung, I.H. (2014) Optimal Treatment Strategy for a Tumor Model under Immune Suppression. Computational and Mathematical Methods in Medicine, 2014, 206287. https://doi.org/10.1155/2014/206287
Del Monte, U. (2009) Does the Cell Number 10(9) Still Really Fit one Gram of Tumor Tissue? Cell Cycle, 8, 505-506. https://doi.org/10.4161/cc.8.3.7608
Whiteside, T.L. (2010) Inhibiting the Inhibitors: Evaluating Agents Targeting Cancer Immunosuppression. Expert Opinion on Biological Therapy, 10, 1019-1035. https://doi.org/10.1517/14712598.2010.482207
Facciabene, A., Motz, G.T. and Coukos, G. (2012) T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. Cancer Research, 72, 2162-2171. https://doi.org/10.1158/0008-5472.CAN-11-3687
Neuzillet, C., et al. (2015) Targeting the TGFβ Pathway for Cancer Therapy. Pharmacology & Therapeutics, 147, 22-31. https://doi.org/10.1016/j.pharmthera.2014.11.001
Niu, G. and Chen, X. (2010) Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy. Current Drug Targets, 11, 1000-1017. https://doi.org/10.2174/138945010791591395
Carmeliet, P. (2005) VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology, 69, 4-10. https://doi.org/10.1159/000088478
Asadullah, K., Sterry, W. and Volk, H.D. (2003) Interleukin-10 Therapy—Review of a New Approach. Pharmacological Reviews, 55, 241-269. https://doi.org/10.1124/pr.55.2.4
Wang, L., Liu, J.-Q., Talebian, F., Liu, Z., Yu, L. and Bai, X.-F. (2015) IL-10 Enhances CTL-Mediated Tumor Rejection by Inhibiting Highly Suppressive CD4+T Cells and Promoting CTL Persistence in a Murine Model of Plasmacytoma. Oncoimmunology, 4, e1014232.
Oft, M. (2014) IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunology Research, 2, 194-199. https://doi.org/10.1158/2326-6066.CIR-13-0214
Morris, J.C., et al. (2014) Phase I study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. PLoS One, 9, e90353. https://doi.org/10.1371/journal.pone.0090353
Ishida, H., Muchamuel, T., Sakaguchi, S., Andrade, S., Menon, S. and Howard, M. (1994) Continuous Administration of Anti-Interleukin 10 Antibodies Delays Onset of Autoimmunity in NZB/W F1 Mice. The Journal of Experimental Medicine, 179, 305-310. https://doi.org/10.1084/jem.179.1.305
DePillis, L., Caldwell, T., Sarapata, E. and Williams, H. (2013) Mathematical Modeling of Regulatory T Cell Effects on Renal Cell Carcinoma Treatment. Discret. Contin. Dyn. Syst. - Ser. B, 18, 915-943.
Sakamoto, N., et al. (2015) Phase I Clinical Trial of Autologous NK Cell Therapy Using Novel Expansion Method in Patients with Advanced Digestive Cancer. Journal of Translational Medicine, 13, 277. https://doi.org/10.1186/s12967-015-0632-8
Kronik, N., Kogan, Y., Vainstein, V. and Agur, Z. (2008) Improving Alloreactive CTL Immunotherapy for Malignant Gliomas Using a Simulation Model of Their Interactive Dynamics. Cancer Immunology, Immunotherapy, 57, 425-439. https://doi.org/10.1007/s00262-007-0387-z
Rosenberg, S.A. (2014) IL-2: The First Effective Immunotherapy for Human Cancer. The Journal of Immunology, 192, 5451-5458. https://doi.org/10.4049/jimmunol.1490019
de Pillis, L., et al. (2009) Mathematical Model Creation for Cancer Chemo-Immunotherapy. Computational and Mathematical Methods in Medicine, 10, 165-184. https://doi.org/10.1080/17486700802216301
Arciero, J.C., Jackson, T.L. and Kirschner, D.E. (2004) A Mathematical Model of Tumor-Immune Evasion and siRNA Treatment. Discret. Contin. Dyn. Syst. - Ser. B, 4, 39-58.
Robertson-Tessi, M., El-Kareh, A. and Goriely, A. (2012) A Mathematical Model of Tumor-Immune Interactions. Journal of Theoretical Biology, 294, 56-73. https://doi.org/10.1016/j.jtbi.2011.10.027
Bian, X., et al. (2006) Increased Angiogenic Capabilities of Endothelial Cells from Microvessels of Malignant Human Gliomas. International Immunopharmacology, 6, 90-99. https://doi.org/10.1016/j.intimp.2005.08.004
Hahnfeldt, P., Panigrahy, D., Folkman, J. and Hlatky, L. (1999) Tumor Development under Angiogenic Signaling: A Dynamical Theory of Tumor Growth, Treatment Response, and Postvascular Dormancy. Cancer Research, 59, 4770-4775.
Mabarrack, N.H.E., Turner, N.L. and Mayrhofer, G. (2008) Recent Thymic Origin, Differentiation, and Turnover of Regulatory T Cells. Journal of Leukocyte Biology, 84, 1287-1297. https://doi.org/10.1189/jlb.0308201
Sun, X., et al. (2016) Mathematical Modeling of Therapy-Induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Scientific Reports, 6, 22498. https://doi.org/10.1038/srep22498
Cameron, M.A., Davis, A.L., Kostelich, E. and Eikenberry, S. (2009) A Mathematical Model of Angiogenesis in Glioblastoma Multiforme. Arizona State University, Tempe.